Geographic Reach International HIFU operates treatment centers across North America and international locations including the Bahamas, Mexico, Bermuda, Canada, and multiple countries in Europe and Asia, presenting opportunities to partner with international clinics and distributors to expand Sonablate 500 adoption.

Targeted Prostate Focus With the Sonablate 500 being a key offering for prostate cancer treatment and approved outside the US in over 30 countries, there is potential to engage urology practices, cancer centers, and ambulatory surgery programs seeking non-invasive treatment options for patients.

SMB Growth Potential As a small to mid-sized company (11-50 employees) with under $1M in revenue, there is room to scale via channel partnerships, regional distributors, and service contracts with existing international centers to increase utilization and recurring revenue.

Strategic Partnerships Leverage relationships with physicians and North American treatment centers to co-market and expand into new markets, including Caribbean and European territories, by offering training, service support, and turnkey implementation for new sites.

Competitive Positioning Position Sonablate 500 as a globally accessible, doctor-recommended HIFU solution with proven international footprint to differentiate from competitors and target markets where access to minimally invasive prostate cancer therapies is limited.